Literature DB >> 8094831

Persistence of initial infection in recurrent Cryptococcus neoformans meningitis.

E D Spitzer1, S G Spitzer, L F Freundlich, A Casadevall.   

Abstract

Patients with cryptococcal meningitis tend to have recurrences of infection. Although the original strain of Cryptococcus neoformans is assumed to persist in recurrent infections, this assumption has not been tested. Southern blot hybridisation with two genomic DNA probes and pulsed-field electrophoresis of intact chromosomes were used to investigate the genetic relation between initial and relapse isolates of C neoformans from patients with recurrent cryptococcal meningitis. Eleven isolates were obtained from four patients (three with AIDS, one with leukaemia). Isolates from each patient could be distinguished from those of the other patients; however, each patient's initial and recurrence isolates were clonally related. Our results provide strong evidence that clinical recurrences of cryptococcal meningitis result from persistence of the original infecting strain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094831     DOI: 10.1016/0140-6736(93)90354-j

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  76 in total

Review 1.  The ins and outs of DNA fingerprinting the infectious fungi.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

2.  It infects me, it infects me not: phenotypic switching in the fungal pathogen Cryptococcus neoformans.

Authors:  C A D'Souza; J Heitman
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

3.  Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure.

Authors:  S P Franzot; J S Hamdan; B P Currie; A Casadevall
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

4.  G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate.

Authors:  Laura Rodero; Emilia Mellado; A Carolina Rodriguez; Angela Salve; Liliana Guelfand; Pedro Cahn; Manuel Cuenca-Estrella; Graciela Davel; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

5.  Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B.

Authors:  N Mozaffarian; J W Berman; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

6.  Requirement for CD4(+) T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice.

Authors:  K L Buchanan; H A Doyle
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 7.  Phenotypic switching and its implications for the pathogenesis of Cryptococcus neoformans.

Authors:  Neena Jain; Abraham Guerrero; Bettina C Fries
Journal:  FEMS Yeast Res       Date:  2006-06       Impact factor: 2.796

8.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group.

Authors:  M E Brandt; L C Hutwagner; L A Klug; W S Baughman; D Rimland; E A Graviss; R J Hamill; C Thomas; P G Pappas; A L Reingold; R W Pinner
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.